Teva Company Profile

What is the competitive landscape for TEVA

TEVA has seven hundred and forty-one approved drugs.

There are fifty-two US patents protecting TEVA drugs. There are fifty-three tentative approvals on TEVA drugs.

There are eight hundred and eighty-six patent family members on TEVA drugs in forty-seven countries and one thousand one hundred and eighty-five supplementary protection certificates in nineteen countries.

Summary for Teva

International Patents:	886
US Patents:	52
Tradenames:	513
Ingredients:	448
NDAs:	741
Patent Litigation for Teva:	See patent lawsuits for Teva
PTAB Cases with Teva as petitioner:	See PTAB cases with Teva as petitioner

Drugs and US Patents for Teva

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms Usa	IMATINIB MESYLATE	imatinib mesylate	TABLET;ORAL	204285-001	Aug 4, 2016	AB	RX	No	No
Teva Pharms Usa	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	210876-002	Jan 31, 2022	AB2	RX	No	No
Teva Pharms	VARDENAFIL HYDROCHLORIDE	vardenafil hydrochloride	TABLET;ORAL	091347-004	May 3, 2012	AB	RX	No	No
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE;ORAL	216354-005	May 29, 2024		RX	Yes	No	11,813,232*PED				Y
Teva	NEFAZODONE HYDROCHLORIDE	nefazodone hydrochloride	TABLET;ORAL	076037-003	Sep 16, 2003		RX	No	No
Teva Pharms Usa	IFOSFAMIDE/MESNA KIT	ifosfamide; mesna	INJECTABLE;INTRAVENOUS	075874-001	Feb 26, 2002		DISCN	No	No
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE;ORAL	216354-008	Jul 1, 2024		RX	Yes	No	10,959,996*PED				Y

Expired US Patents for Teva

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva	UZEDY	risperidone	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	213586-004	Apr 28, 2023	10,736,965
Teva Branded Pharm	SEASONALE	ethinyl estradiol; levonorgestrel	TABLET;ORAL	021544-001	Sep 5, 2003	5,898,032
Teva	UZEDY	risperidone	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	213586-007	Apr 28, 2023	9,717,799
Teva Pharm	ARMONAIR DIGIHALER	fluticasone propionate	POWDER;INHALATION	208798-004	Feb 20, 2020	6,871,646
Teva Pharm	AIRDUO DIGIHALER	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-004	Jul 12, 2019	6,701,917
Teva Pharm	ARMONAIR DIGIHALER	fluticasone propionate	POWDER;INHALATION	208798-006	Feb 20, 2020	6,718,972
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-003	Jan 27, 2017	6,871,646

Paragraph IV (Patent) Challenges for TEVA drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	5 mg, 10 mg, 20 mg, 30 mg		2009-11-18
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-02-26
	Tablets	0.15 mg/0.03 mg/0.01 mg		2008-01-22
	Tablets	0.1 mg/0.02 mg and 0.01 mg		2009-11-16
	for Injection	3.5 mg/vial		2016-10-26
	Tablets	0.5 mg and 1 mg		2010-05-17
	Extended-release Capsule	15 mg and 30 mg		2008-08-11
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-01-29
	Tablets	0.15 mg/0.03 mg		2004-03-29
	Tablets	0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg		2013-07-10
	Tablets	1 mg/0.02 mg and 75 mg		2006-04-17
	Delayed-release Tablets	20 mg		2015-06-03

International Patents for Teva Drugs

Country	Patent Number	Estimated Expiration
Austria	451106
Mexico	2016004316
Poland	3568181
Spain	2927262
Japan	2015231585
South Korea	20130103823
Israel	244802

Supplementary Protection Certificates for Teva Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0900210	C00900210/01	Switzerland		PRODUCT NAME: ATAZANAVIR; REGISTRATION NUMBER/DATE: SWISSMEDIC 56288 06.05.2004
1280520	122015000021	Germany		PRODUCT NAME: TOBRAMYCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/10/652/001-003 20110720
0579826	SPC/GB02/042	United Kingdom		PRODUCT NAME: ERTAPENEM ((1R,5S,6S,8R,2'S,4'S)-2-(2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO)-6-(1-HYDROXYETHYL)-1-METHYLCARBAPENEM-3-CARBOXYLIC ACID), A PHARMACEUTICALLY ACCEPTABLE SALT OR IN VIVO HYDROLYSABLE ESTER THEREOF, ESPECIALLY AS THE MONOSODIUM SALT ERTA; REGISTERED: UK EU/1/02/216/001 20020422
0477295	C990043	Netherlands		PRODUCT NAME: EPTIFIBATIDE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NAT. REGISTRATION NO/DATE: EU/1/99/109/001 - EU/1/99/109/002 19990701; FIRST REGISTRATION: CH 54050, 54054 19970227
1453521	132016000025143	Italy		PRODUCT NAME: LEVONORGESTREL ED ETINILESTRADIOLO(SEASONIQUE); AUTHORISATION NUMBER(S) AND DATE(S): 17/0017/15-S, 20150211;042139016, 20150414
0503785	C300375	Netherlands		PRODUCT NAME: COMBINATIE VAN OLMESARTAN MEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT EN AMLODIPINEBESILAAT; REGISTRATION NO/DATE: RVG100984, RVG100986-87, RVG100989-91, RVG100993-95 20080819
1110543	SPC/GB08/005	United Kingdom		SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Teva
• Teva Branded Pharm
• Teva Parenteral
• Teva Pharm
• Teva Pharms
• Teva Pharms Inc
• Teva Pharms Intl

Pharmaceutical Competitive Landscape Analysis: Teva – Market Position, Strengths & Strategic Insights

Last updated: February 19, 2026

How does Teva position itself within the global generic and specialty pharmaceutical markets?

Teva Pharmaceutical Industries Ltd. ranks among the largest global generic drug manufacturers with a revenue of approximately $10.4 billion in 2022. Its portfolio includes over 3,500 generic medicines spanning various therapeutic areas such as analgesics, respiratory, and central nervous system (CNS) treatments. The company maintains a significant presence in North America, Europe, and emerging markets.

In 2022, Teva's market share in the U.S. generic market reached an estimated 8%, positioning it as the third-largest generic manufacturer. Its core strategy involves leveraging manufacturing scale, diversified product offerings, and cost efficiencies to compete against both generic rivals and branded pharmaceutical companies transitioning to biosimilars.

What are Teva’s key strengths in the competitive landscape?

• Manufacturing Scale and Supply Chain Verticals: Teva owns approximately net 26 manufacturing facilities globally, which facilitates high-volume production, cost control, and supply chain resilience.

• Product Diversification: With over 3,500 generic SKUs, Teva covers broad therapeutic areas, reducing revenue dependence on any single franchise.

• Biosimilar Pipeline: The company has an active biosimilars portfolio, including products such as trastuzumab and adalimumab, aligned with the industry shift toward complex biologics.

• Market Presence in the U.S.: Teva's U.S. business accounts for roughly 75% of its revenue, supported by established sales channels and regulatory approvals for key generic products.

What are the main challenges faced by Teva?

• Legal and Patent Litigation: Ongoing patent disputes and litigation expenses have led to billions in liabilities and product losses, notably for drugs like generic sildenafil and multiple branded products losing patent exclusivity.

• Pricing Pressures: Heightened competition in generic markets results in declining prices and narrower profit margins.

• Debt Burden: Post-2016 debt restructuring left Teva with more than $25 billion in debt, constraining capital allocation and strategic investments.

• Pipeline Risks: While biosimilars offer growth potential, delays in regulatory approval and market entry pose significant risks.

How does Teva’s strategic positioning compare to key competitors?

Company	Market Focus	Revenue (2022)	Core Strengths	Notable Challenges
Teva	Generics, biosimilars	$10.4B	Manufacturing scale, product breadth, biosimilar pipeline	Debt, legal liabilities, pricing pressures
Sanfofi	Branded, generics	$41.4B	Innovator pipeline, specialty drugs	Generic competition, pricing pressure
Mylan (now part of Viatris)	Generics, biosimilars	$17.7B	Cost efficiencies, global footprint	Market fragmentation, regulatory hurdles
Novartis	Branded, biosimilars	$51.6B	Innovator R&D, biosimilars	Patent cliffs, R&D costs

Teva’s focus on high-volume generics contrasts with Novartis’s emphasis on innovative branded drugs. Its biosimilar development compares favorably with Viatris, though the latter benefits from broader generic diversification.

What strategic initiatives are key to Teva’s future growth?

• Biosimilar Expansion: Investing in late-stage biosimilar development to capture biologic market share. The pipeline includes a biosimilar trastuzumab, launched in select markets.

• Portfolio Optimization: Divesting non-core assets to reduce debt and improve cash flow. Recently, Teva sold its manufacturing facilities in Italy for approximately $175 million.

• Emerging Market Penetration: Expanding presence in Latin America, Asia, and Africa to capitalize on rising healthcare access.

• Operational Efficiency: Streamlining manufacturing processes to reduce costs and improve margin stability.

What regulatory and market risk factors will shape Teva’s outlook?

• Patent Cliff Impacts: The expiry of key patents continues to erode revenues from flagship branded drugs such as Copaxone. Teva reports that generic versions of Copaxone eroded approximately $1.4 billion of its revenue over 2020–2021.

• Regulatory Delays: Biosimilar approvals face lengthy review cycles; in the U.S., regulatory agencies require extensive data packages, which prolong market entry.

• Price Controls and Reimbursement Policies: Governments, especially in Europe and North America, implement initiatives to curb drug prices, impacting profitability.

What does the competitive future landscape look like?

The generic and biosimilar space will face increased competition as market entrants leverage advanced manufacturing and AI-driven R&D. Companies like Biogen and Samsung Bioepis expand biosimilar pipelines, threatening Teva’s anticipated growth from this sector. Mergers and acquisitions in the sector aim to consolidate market share and R&D resources, potentially redefining competitive dynamics.

Key Takeaways

• Teva remains a leading generic manufacturer with strategic investments in biosimilars and emerging markets.
• The company’s debt and legal liabilities present headwinds for financial flexibility.
• Biosimilar development is central to future growth but entails regulatory and competitive risks.
• Diversification and operational efficiencies are critical to sustain profitability amid pricing pressures.
• Mergers of competitors and policy shifts in pricing present ongoing challenges and opportunities.

FAQs

1. How significant is Teva’s biosimilar pipeline?
Teva’s biosimilar pipeline includes products like trastuzumab and adalimumab, with some launched in select markets. The pipeline is considered strategic, with potential to capture sizeable biologic markets if approvals occur timely.

2. What impact did patent expirations have on Teva’s revenue?
Patent expirations, primarily for Copaxone, reduced revenue by approximately $1.4 billion in 2020–2021. Further patent cliffs are expected in the coming years, affecting financial stability.

3. How does Teva’s debt load affect its strategic options?
Post-2016 restructuring, Teva’s debt exceeds $25 billion, limiting capital expenditure, R&D investments, and acquisition activity. Debt repayment obligations also influence dividend and share repurchase policies.

4. What are the main risks for Teva in the coming years?
Key risks include delays in biosimilar approvals, intensified pricing pressures, patent cliffs, legal liabilities, and potential mergers among competitors impacting market shares.

5. Which markets are priorities for Teva’s expansion?
Emerging markets in Latin America, Southeast Asia, and Africa are targeted for expansion to offset mature market saturation and benefit from increasing healthcare spending.

---

References

1. Bloomberg. (2023). Teva Pharmaceutical Industries Ltd. Financials and market data.
2. Teva Pharmaceutical Industries Ltd. Annual Report 2022.
3. IQVIA. (2022). Global Generic Market Report.
4. FDA. (2023). Biosimilar Approval Process Overview.
5. European Medicines Agency. (2022). Biosimilar Market and Regulatory Outlook.[1][2][3][4][5]